1. Home
  2. NWS vs BIIB Comparison

NWS vs BIIB Comparison

Compare NWS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NWS
  • BIIB
  • Stock Information
  • Founded
  • NWS 2012
  • BIIB 1978
  • Country
  • NWS United States
  • BIIB United States
  • Employees
  • NWS N/A
  • BIIB N/A
  • Industry
  • NWS Newspapers/Magazines
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • NWS Consumer Discretionary
  • BIIB Health Care
  • Exchange
  • NWS Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • NWS 19.1B
  • BIIB 18.7B
  • IPO Year
  • NWS N/A
  • BIIB 1991
  • Fundamental
  • Price
  • NWS $33.67
  • BIIB $144.12
  • Analyst Decision
  • NWS Strong Buy
  • BIIB Buy
  • Analyst Count
  • NWS 7
  • BIIB 27
  • Target Price
  • NWS $38.28
  • BIIB $188.09
  • AVG Volume (30 Days)
  • NWS 1.5M
  • BIIB 1.5M
  • Earning Date
  • NWS 11-06-2025
  • BIIB 10-29-2025
  • Dividend Yield
  • NWS 0.60%
  • BIIB N/A
  • EPS Growth
  • NWS 345.01
  • BIIB 31.67
  • EPS
  • NWS 2.07
  • BIIB 10.45
  • Revenue
  • NWS $8,452,000,000.00
  • BIIB $9,997,000,000.00
  • Revenue This Year
  • NWS $4.80
  • BIIB $2.00
  • Revenue Next Year
  • NWS $3.74
  • BIIB N/A
  • P/E Ratio
  • NWS $16.00
  • BIIB $13.83
  • Revenue Growth
  • NWS 2.42
  • BIIB 3.36
  • 52 Week Low
  • NWS $26.25
  • BIIB $110.04
  • 52 Week High
  • NWS $35.58
  • BIIB $204.18
  • Technical
  • Relative Strength Index (RSI)
  • NWS 53.12
  • BIIB 57.71
  • Support Level
  • NWS $31.56
  • BIIB $141.12
  • Resistance Level
  • NWS $34.07
  • BIIB $147.23
  • Average True Range (ATR)
  • NWS 0.69
  • BIIB 4.55
  • MACD
  • NWS 0.02
  • BIIB 0.08
  • Stochastic Oscillator
  • NWS 83.00
  • BIIB 64.98

About NWS News Corporation Class B

News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Share on Social Networks: